Bedrijfsoverzicht
uniQure N.V. is a biotechnology enterprise dedicated to developing advanced treatments for patients suffering from rare and devastating diseases within the United States, with a specific focus on delivering gene therapies such as HEMGENIX for hemophilia B. The company operates within the broader healthcare sector and functions specifically in the biotechnology industry, an environment characterized by high regulatory standards and significant research and development expenditures aimed at addressing unmet medical needs. This biotechnology firm currently maintains a market capitalization of $961.70M and employs a workforce of 221 individuals to advance its therapeutic pipeline. The combination of a market cap near $1 billion and annual revenue of $16.10M indicates that the company operates as a mid-cap entity that is still in a phase of scaling operations, where revenue generation is currently limited but the market valuation reflects substantial investor confidence in the potential of its lead product candidate, AMT-130.
Financiële gezondheid
The company reported total revenue of $16.10M over the trailing twelve months, yet this revenue figure stands in stark contrast to a net income loss of $198,971,008, revealing a cost structure where expenses vastly outweigh current earnings. EBITDA for the period was recorded at $-164,343,008, further underscoring the heavy burn rate typical of clinical-stage biotechnology companies that prioritize R&D and clinical trials over immediate profitability. Free cash flow stood at $-106,758,000, indicating a significant cash outflow required to fund ongoing operations and development activities, which limits immediate financial flexibility but is a common characteristic for firms in the early commercialization phase. The gross margin is listed at 0.0%, while the operating margin is -900.9% and the profit margin is 0.0%, all figures reflecting the current inability to generate profit from sales due to the high cost of goods and operating expenses relative to the current revenue base. Regarding liquidity, the company holds $622.54M in cash against $536.59M in debt, resulting in a debt-to-equity ratio of 269.78, which suggests a highly leveraged balance sheet that relies heavily on its cash reserves to service obligations. The current ratio is an exceptionally high 10.43, indicating strong short-term liquidity and an ability to cover current liabilities many times over with available current assets. Return on Equity is -207.1% and Return on Assets is -16.2%, metrics that reveal management is currently utilizing the company's capital and asset base to generate negative returns as it invests heavily into the future growth of its therapeutic pipeline rather than returning value through profits.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is calculated at -5.64, a metric that implies earnings are not yet positive and that the market is pricing the stock based on future expectations rather than historical profitability. The price-to-book ratio stands at 4.82, indicating that the market values the company at nearly five times its book value, which suggests a significant premium assigned to the company's intangible assets, intellectual property, and future revenue potential that are not captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 59.74 and an EV/EBITDA of -5.33 further highlight the speculative nature of the valuation, as investors are willing to pay a high multiple for every dollar of sales generated given the high growth potential of gene therapies. The stock has exhibited significant volatility over the past year, trading between a 52-week low of $8.66 and a 52-week high of $71.50, meaning the current price position is highly dependent on recent market sentiment and clinical trial data updates. The beta value of 0.75 indicates that the stock's price volatility is lower than the broader market, suggesting that while the company carries high business risk due to its development stage, its price movements are less sensitive to general market fluctuations compared to the S&P 500.
Growth & Income
Revenue growth year-over-year is reported at 6.6%, whereas earnings growth is N/A due to the company's continued net losses, implying that revenue expansion is currently outpacing the reduction of losses as the business scales. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, as evidenced by the 0.0% payout ratio figure, meaning that all available cash flow is reinvested directly into research, development, and commercialization efforts rather than being distributed to shareholders. The absence of a dividend yield confirms that the company follows a growth-oriented capital allocation strategy typical of biotechnology firms, prioritizing the advancement of its pipeline over providing regular income to investors. In summary, uniQure N.V. presents a growth profile defined by modest revenue expansion and a complete lack of income distribution, reflecting a business model focused entirely on long-term value creation through the successful deployment of its gene therapy treatments.